GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.
Level 5 - mechanism / opinion, no new human data
Narrative review of mechanisms and clinical evidence without systematic review methodology
PubMed 33068776 · doi:10.1016/j.molmet.2020.101102
What was done
This narrative review summarizes the pharmacology, formulations (twice-daily, once-daily, once-weekly, and daily oral), glycemic mechanisms, weight loss effects, and cardiovascular outcome trials of GLP-1 receptor agonists for type 2 diabetes management.
What was found
The abstract reports no numerical values. It describes that short-acting agents preserve gastric emptying delay over time but have weaker effects on fasting glucose, whereas long-acting formulations achieve greater HbA1c and fasting glucose reductions with tachyphylaxis to gastric emptying delay. Cardiovascular outcome trials demonstrated reductions in acute myocardial infarction, stroke, and mortality, predominantly in patients with pre-existing atherosclerotic cardiovascular disease.
Why it matters
The paper synthesizes the evidence establishing GLP-1 receptor agonists as preferred first-line injectable agents ahead of insulin, highlighting their joint metabolic and cardioprotective benefits.
Limits
As a narrative review, it lacks a systematic literature search and quantitative effect estimates. The abstract notes that cardiovascular benefit evidence is less robust in lower-risk populations compared to those with established atherosclerotic disease.
Cited by
- supports GLP-1 receptor agonist drugs have been in medical use for approximately 20 years.